WO2002083079A3 - Aerosol compositions containing formoterol for delivery to the lungs via nebulization - Google Patents

Aerosol compositions containing formoterol for delivery to the lungs via nebulization Download PDF

Info

Publication number
WO2002083079A3
WO2002083079A3 PCT/US2002/006240 US0206240W WO02083079A3 WO 2002083079 A3 WO2002083079 A3 WO 2002083079A3 US 0206240 W US0206240 W US 0206240W WO 02083079 A3 WO02083079 A3 WO 02083079A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
compositions containing
aerosol compositions
lungs via
via nebulization
Prior art date
Application number
PCT/US2002/006240
Other languages
French (fr)
Other versions
WO2002083079A2 (en
WO2002083079A9 (en
Inventor
Partha S Banerjee
Stephen Pham
Samuel O Akapo
Imtiaz A Chaudry
Original Assignee
Dey L P
Partha S Banerjee
Stephen Pham
Samuel O Akapo
Imtiaz A Chaudry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002083079(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dey L P, Partha S Banerjee, Stephen Pham, Samuel O Akapo, Imtiaz A Chaudry filed Critical Dey L P
Priority to CA2438544A priority Critical patent/CA2438544C/en
Priority to SI200231067T priority patent/SI1381346T1/en
Priority to ES02709742.7T priority patent/ES2554476T3/en
Priority to AU2002244211A priority patent/AU2002244211B2/en
Priority to JP2002580884A priority patent/JP2004532217A/en
Priority to EP02709742.7A priority patent/EP1381346B1/en
Publication of WO2002083079A2 publication Critical patent/WO2002083079A2/en
Publication of WO2002083079A3 publication Critical patent/WO2002083079A3/en
Publication of WO2002083079A9 publication Critical patent/WO2002083079A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
PCT/US2002/006240 2001-04-17 2002-02-28 Aerosol compositions containing formoterol for delivery to the lungs via nebulization WO2002083079A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2438544A CA2438544C (en) 2001-04-17 2002-02-28 Aerosol compositions containing formoterol for delivery to the lungs via nebulization
SI200231067T SI1381346T1 (en) 2001-04-17 2002-02-28 Pharmaceutical compositions containing formoterol
ES02709742.7T ES2554476T3 (en) 2001-04-17 2002-02-28 Pharmaceutical compositions containing formoterol
AU2002244211A AU2002244211B2 (en) 2001-04-17 2002-02-28 Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization
JP2002580884A JP2004532217A (en) 2001-04-17 2002-02-28 Formoterol-containing aerosol compositions for delivery to the lung via nebulization
EP02709742.7A EP1381346B1 (en) 2001-04-17 2002-02-28 Pharmaceutical compositions containing formoterol

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28460601P 2001-04-17 2001-04-17
US60/284,606 2001-04-17
US09/887,281 US6667344B2 (en) 2001-04-17 2001-06-22 Bronchodilating compositions and methods
US09/887,281 2001-06-22

Publications (3)

Publication Number Publication Date
WO2002083079A2 WO2002083079A2 (en) 2002-10-24
WO2002083079A3 true WO2002083079A3 (en) 2003-02-13
WO2002083079A9 WO2002083079A9 (en) 2003-04-10

Family

ID=26962700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/006240 WO2002083079A2 (en) 2001-04-17 2002-02-28 Aerosol compositions containing formoterol for delivery to the lungs via nebulization

Country Status (9)

Country Link
US (2) US6667344B2 (en)
EP (1) EP1381346B1 (en)
JP (4) JP2004532217A (en)
AU (1) AU2002244211B2 (en)
CA (1) CA2438544C (en)
ES (1) ES2554476T3 (en)
PT (1) PT1381346E (en)
SI (1) SI1381346T1 (en)
WO (1) WO2002083079A2 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AU2001294808A1 (en) * 2000-09-29 2002-04-08 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20020187099A1 (en) * 2001-05-16 2002-12-12 Rajesh Manchanda Stabilization of radionuclide-containing compositions
WO2002096422A2 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
AU2003273328A1 (en) * 2002-09-18 2004-04-08 Infineon Technologies Ag Nitride and polysilicon interface with titanium layer
US20040110845A1 (en) * 2002-12-06 2004-06-10 Ramana Malladi Stabilized albuterol compositions and method of preparation thereof
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
EP1603810B1 (en) * 2003-03-15 2010-08-11 Brin Tech International Limited Medicament package
SE0301260D0 (en) * 2003-04-29 2003-04-29 Astrazeneca Ab Novel equipment
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US9675637B2 (en) 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050042176A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a steroid
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US7943699B2 (en) 2003-10-21 2011-05-17 E. I. Du Pont De Nemours And Company Ethylene copolymer modified oriented polyester films, tapes, fibers and nonwoven textiles
PE20050941A1 (en) 2003-12-16 2005-11-08 Nycomed Gmbh AQUEOUS CYCLESOUND SUSPENSIONS FOR MISTING
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
JP4700014B2 (en) * 2004-02-06 2011-06-15 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Combination of anticholinergic agent and type 4 phosphodiesterase for the treatment of respiratory diseases
SI1713473T1 (en) * 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
CN1905902A (en) * 2004-02-06 2007-01-31 Meda制药有限及两合公司 Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases
WO2005097095A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
WO2005123072A1 (en) * 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
EP1791534A1 (en) * 2004-09-09 2007-06-06 Cipla Ltd. Pharmaceutical composition comprising an isomer of a betamimetic agent and an anti-cholinergic agent
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
CA2608752A1 (en) * 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US8557300B2 (en) * 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
CN101198313A (en) * 2005-08-01 2008-06-11 奇斯药制品公司 Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
ES2318794T3 (en) * 2005-09-21 2009-05-01 Pfizer Limited CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF MUSCARINIC RECEPTORS.
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
CA2652797A1 (en) * 2006-05-18 2007-11-29 Tika Laekemedel Ab Methods for the delivery of a .beta.2 agonist to induce bronchodilation and formulations for use in the same
EP2034990A4 (en) * 2006-05-26 2013-03-06 Dey L P Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
EP1925296A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
US20100260853A1 (en) * 2007-12-13 2010-10-14 Amrik Basran Compositions for pulmonary delivery
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
RU2577698C2 (en) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Dry powder formulations and methods of treating pulmonary diseases
CN101544386B (en) * 2009-04-29 2011-01-05 余荣华 Method for producing potassium nitrate together with ammonium chloride and ammonium nitrate
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL2435025T3 (en) 2009-05-29 2017-08-31 Pearl Therapeutics, Inc. Respiratory delivery of active agents
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
DK2515854T3 (en) 2009-12-23 2014-05-26 Chiesi Farma Spa Aerosol formulation for COPD
CN104055765B (en) 2009-12-23 2016-11-23 奇斯药制品公司 Therapeutic alliance for COPD
IN2012DN05192A (en) * 2010-01-21 2015-10-23 Aprea Ab
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CN105640925B (en) 2010-08-30 2019-08-16 普马特里克斯营业公司 Dried powder formula and method for treating pulmonary disease
CN102416179B (en) 2010-09-28 2014-05-07 益得生物科技股份有限公司 Inhaled compound composition for asthma
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
KR101915241B1 (en) 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 Monovalent metal cation dry powders for inhalation
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN109999013A (en) 2012-02-29 2019-07-12 普马特里克斯营业公司 Inhalable dry powder doses
TR201902687T4 (en) 2013-03-15 2019-03-21 Pearl Therapeutics Inc Methods and systems for conditioning coarse crystalline materials.
RU2015146871A (en) 2013-04-01 2017-05-10 Пулматрикс, Инк. DRY POWDERS WITH THIOTROPY
CN107224427A (en) * 2013-07-01 2017-10-03 成都苑东生物制药股份有限公司 A kind of Glycopyrronium bromide injection composition and preparation method thereof
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
CN107847432A (en) 2015-05-29 2018-03-27 西德奈克西斯公司 D2The stabilized pharmaceutical preparations of O
CN107362140A (en) * 2016-05-11 2017-11-21 广东东阳光药业有限公司 Spray and spray assembly
MX2019004366A (en) * 2016-10-14 2019-08-05 Glenmark Specialty Sa Nebulizable compositions of tiotropium and formoterol.
CN108853011B (en) * 2018-06-13 2021-01-29 北京华润高科天然药物有限公司 Calcium gluconate-L-calcium lactate oral liquid and preparation method thereof
EP3893862B1 (en) * 2018-12-14 2023-11-22 National Taiwan University A stable cardioplegic solution for cardiac surgery
CN112870172B (en) * 2019-11-29 2022-09-13 北京福元医药股份有限公司 Montelukast sodium pharmaceutical preparation
US20210275449A1 (en) * 2020-03-01 2021-09-09 Cai Gu Huang Inhalable Formulation of a Solution Containing Glycopyrronium Bromide
CN112326808A (en) * 2020-09-24 2021-02-05 南京斯泰尔医药科技有限公司 Method for determining content of sodium metabisulfite in injection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370632A1 (en) * 1988-11-04 1990-05-30 FISONS plc Pharmaceutical solution containing salbutamol and cromoglycic acid
WO1995031964A1 (en) * 1994-05-21 1995-11-30 Glaxo Wellcome Australia Limited Fluticasone propionate formulations
WO1999025359A1 (en) * 1997-11-14 1999-05-27 Astrazeneca Ab New composition of matter
WO2000000181A1 (en) * 1998-06-26 2000-01-06 Lds Technologies, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO2000023037A1 (en) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Two chamber cartridge for atomizers
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
DE2366625C2 (en) 1972-02-05 1988-06-09 Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp
SE378109B (en) 1972-05-19 1975-08-18 Bofors Ab
PH24267A (en) 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
US4578221A (en) 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
ATE175801T1 (en) 1990-09-18 1999-01-15 Rodime Plc DIGITAL SERVO CONTROL FOR A DISK DRIVE
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5785952A (en) 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
WO1993011744A1 (en) 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
HU227519B1 (en) 1991-12-18 2011-07-28 Astra Ab Synergic pharmaceutical composition containing combination of formoterol and budesonide
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
NZ263084A (en) 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
US5980949A (en) 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
US5647347A (en) 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
DE19541689A1 (en) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Medicament contg. ciclesonid and beta2-sympathomimetic
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
PL320856A1 (en) 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DZ1965A1 (en) 1995-02-06 2002-07-17 Astra Ab New pharmaceutical composition.
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
SE9501384D0 (en) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
SK284448B6 (en) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Metered dose inhaler
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6041777A (en) 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
US5733526A (en) 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
US5753218A (en) 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
SE9603669D0 (en) 1996-10-08 1996-10-08 Astra Ab New combination
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
EP0971698A4 (en) 1996-12-31 2006-07-26 Nektar Therapeutics Aerosolized hydrophobic drug
SE9700135D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
CA2280099C (en) 1997-02-05 2005-12-27 Jago Pharma Ag Medical aerosol formulations
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
CN100548277C (en) 1997-03-20 2009-10-14 先灵公司 The preparation method of powder agglomerates
HUP0002533A3 (en) 1997-06-27 2001-03-28 Astra Ab New combination of antiasthma medicaments
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (en) 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE215820T1 (en) * 1997-10-08 2002-04-15 Sepracor Inc DOSAGE FORM FOR ADMINISTRATION OF AEROSOLS
US5972327A (en) 1997-10-22 1999-10-26 Lin; Matthew M. Method of treating allergic rhinitis by delivering medication via the nasal vestibules
SE9704644D0 (en) 1997-12-12 1997-12-12 Astra Ab New use
WO1999036095A1 (en) 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
WO1999040939A1 (en) 1998-02-10 1999-08-19 Cangene Corporation Method for the prevention and treatment of a type i hypersensitivity disorder
US5972920A (en) 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
US5993782A (en) 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
AU759264B2 (en) 1998-05-27 2003-04-10 Euro-Celtique S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the upper respiratory tract and/or the ear
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US5965622A (en) 1998-06-23 1999-10-12 Sepracor Inc. Desformoterol and process for its preparation
CN1158996C (en) 1998-07-24 2004-07-28 杰格研究股份公司 Medicinal aerosol for mulations
PT1102579E (en) 1998-08-04 2003-07-31 Jago Res Ag MEDICINAL AEROSOL FORMULATIONS
DE19835346A1 (en) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Two-part capsule for pharmaceutical preparations for powder inhalers
US6112924A (en) 1998-09-10 2000-09-05 Bcb Usa, Inc. Container with base having cylindrical legs with circular feet
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
SI1121112T1 (en) * 1998-10-17 2002-10-31 Boehringer Ingelheim Pharma Kg Stable formoterol concentrate
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
IT1303692B1 (en) 1998-11-03 2001-02-23 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION.
DK1283036T3 (en) 1998-11-13 2008-03-25 Jagotec Ag Dry powder for inhalation
SE9804003D0 (en) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804001D0 (en) 1998-11-23 1998-11-23 Astra Ab New process
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900834D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
SE9900833D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
FR2798290B1 (en) 1999-09-11 2003-09-12 Glaxo Group Ltd PHARMACEUTICAL FORMULATION OF FLUTICASONE PROPIONATE
DE19947235A1 (en) 1999-09-30 2001-04-05 Asta Medica Ag New combination of loteprednol and beta¶2¶ adrenoreceptor agonists
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9903995D0 (en) 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
JP2003531123A (en) 2000-04-13 2003-10-21 イノバータ・バイオミッド・リミテッド Medicine
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
JP5392880B2 (en) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Stable pharmaceutical solution formulation for pressurized metered dose inhalers
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
DE60203652T2 (en) 2001-01-31 2005-09-08 Pfizer Products Inc., Groton Nicotinic acid amide derivatives and their mimetics as inhibitors of PDE4 isozymes
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370632A1 (en) * 1988-11-04 1990-05-30 FISONS plc Pharmaceutical solution containing salbutamol and cromoglycic acid
WO1995031964A1 (en) * 1994-05-21 1995-11-30 Glaxo Wellcome Australia Limited Fluticasone propionate formulations
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999025359A1 (en) * 1997-11-14 1999-05-27 Astrazeneca Ab New composition of matter
WO2000000181A1 (en) * 1998-06-26 2000-01-06 Lds Technologies, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2000023037A1 (en) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Two chamber cartridge for atomizers
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate

Also Published As

Publication number Publication date
WO2002083079A2 (en) 2002-10-24
EP1381346A2 (en) 2004-01-21
US6667344B2 (en) 2003-12-23
JP6214925B2 (en) 2017-10-18
US6814953B2 (en) 2004-11-09
US20020151598A1 (en) 2002-10-17
CA2438544A1 (en) 2002-10-24
US20020151597A1 (en) 2002-10-17
EP1381346B1 (en) 2015-11-18
JP2015178506A (en) 2015-10-08
PT1381346E (en) 2016-02-04
CA2438544C (en) 2010-11-09
JP2004532217A (en) 2004-10-21
WO2002083079A9 (en) 2003-04-10
JP2009046490A (en) 2009-03-05
SI1381346T1 (en) 2016-03-31
AU2002244211B2 (en) 2007-07-05
ES2554476T3 (en) 2015-12-21
JP2013155208A (en) 2013-08-15

Similar Documents

Publication Publication Date Title
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
WO2005007142A3 (en) Liquid compositions comprising formoterol
WO2002083113A3 (en) Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2005025541A3 (en) Dry powder composition comprising a benzodiazepine for pulmonary inhalation
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
WO2002094342A3 (en) Compositions for protein delivery via the pulmonary route
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2003066597A3 (en) Guanidino compounds
WO2002009679A3 (en) Use of 13-cis retinoic acid for the treatment of emphysema
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
WO2003035080A3 (en) A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
WO2005041922A3 (en) Composition
WO2005065429A3 (en) Composition and method for treatment of hepatic encephalopathy
WO2006019894A3 (en) Nebulized pharmaceutical compositions for the treatment of bronchial disorders
BE2016C017I2 (en)
HK1081862A1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2003013564A3 (en) An herbal composition for the treatment and remedy of bronchial respiratory difficulties
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 8-10, 15, 18, 19 AND 23, DESCRIPTION, REPLACED BY NEW PAGES 8-10, 15, 18, 19 AND 23; PAGE 32,CLAIMS, REPLACED BY A NEW PAGE 32; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

WWE Wipo information: entry into national phase

Ref document number: 2002709742

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2438544

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002244211

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002580884

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002709742

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002244211

Country of ref document: AU